QNCX vs. URGN, FDMT, DSGN, CCCC, CRDF, ALMS, OGI, LFCR, CGEN, and LRMR
Should you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include UroGen Pharma (URGN), 4D Molecular Therapeutics (FDMT), Design Therapeutics (DSGN), C4 Therapeutics (CCCC), Cardiff Oncology (CRDF), Alumis (ALMS), Organigram (OGI), Lifecore Biomedical (LFCR), Compugen (CGEN), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry.
Quince Therapeutics vs.
Quince Therapeutics (NASDAQ:QNCX) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and profitability.
30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 91.3% of UroGen Pharma shares are owned by institutional investors. 16.8% of Quince Therapeutics shares are owned by insiders. Comparatively, 5.1% of UroGen Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Quince Therapeutics has higher earnings, but lower revenue than UroGen Pharma. UroGen Pharma is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, UroGen Pharma had 7 more articles in the media than Quince Therapeutics. MarketBeat recorded 7 mentions for UroGen Pharma and 0 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.00 beat UroGen Pharma's score of -0.09 indicating that Quince Therapeutics is being referred to more favorably in the media.
UroGen Pharma received 361 more outperform votes than Quince Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Quince Therapeutics an outperform vote while only 74.04% of users gave UroGen Pharma an outperform vote.
Quince Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, UroGen Pharma has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.
Quince Therapeutics presently has a consensus target price of $9.50, suggesting a potential upside of 578.57%. UroGen Pharma has a consensus target price of $43.70, suggesting a potential upside of 305.76%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Quince Therapeutics is more favorable than UroGen Pharma.
Quince Therapeutics has a net margin of 0.00% compared to UroGen Pharma's net margin of -129.11%. UroGen Pharma's return on equity of 0.00% beat Quince Therapeutics' return on equity.
Summary
Quince Therapeutics beats UroGen Pharma on 11 of the 18 factors compared between the two stocks.
Get Quince Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Quince Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:QNCX) was last updated on 2/17/2025 by MarketBeat.com Staff